Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.430 Biomarker disease BEFREE Fatty liver may need to be considered as an adverse event for aromatase inhibitor treatment. 30679317 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.430 AlteredExpression disease BEFREE These results strongly suggest that Cyp19 gene disruption, which induces a sexually dimorphic response and high plasma testosterone levels in male mice, also induces hepatic steatosis. 28341248 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.430 GeneticVariation disease BEFREE We aimed to compare the effects of tamoxifen (TMX) and aromatase inhibitors (AIs) on the risk of fatty liver in conjunction with longitudinal changes in the serum lipid parameters. 28651157 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.430 Biomarker disease CTD_human Recently, aromatase-deficient (ArKO, Ar-/-) mice lacking intrinsic estrogen was developed and the molecular mechanism involved in progression of massive hepatic steatosis in estrogen-deficiency was elucidated; impairment in hepatic fatty acid beta-oxidation of peroxisomes, microsomes and mitochondria. 11929713 2002
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.430 Biomarker disease HPO